We are live on ! Find out more
TVTX icon

Travere Therapeutics
TVTX

238 hedge funds and large institutions have $2.41B invested in Travere Therapeutics in 2025 Q3 according to their latest regulatory filings, with 56 funds opening new positions, 72 increasing their positions, 80 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

203% more call options, than puts

Call options by funds: $77.4M | Put options by funds: $25.5M

107% more first-time investments, than exits

New positions opened: 56 | Existing positions closed: 27

62% more capital invested

Capital invested by funds: $1.49B → $2.41B (+$920M)

13% more funds holding

Funds holding: 211 → 238 (+27)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

0.21% less ownership

Funds ownership: 113.24% → 113.03% (-0.21%)

10% less repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 80

Holders
238
Holders Change
+27
Holders Change %
+12.8%
% of All Funds
3.12%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
56
Increased
72
Reduced
80
Closed
27
Calls
$77.4M
Puts
$25.5M
Net Calls
+$51.9M
Net Calls Change
+$26.9M

Top Buyers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
+$55.7M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$34.3M
3
SIMG
Stephens Investment Management Group
Texas
+$30.1M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$21.9M
5
Deutsche Bank
Deutsche Bank
Germany
+$20.4M

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$40.5M
2
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$19M
3
Renaissance Technologies
Renaissance Technologies
New York
-$14M
4
Citadel Advisors
Citadel Advisors
Florida
-$12.2M
5
FLSM
Frazier Life Sciences Management
California
-$11.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
BG
251
Bellevue Group
Switzerland
– -$271K -18,303 Closed
AIM
252
Aigen Investment Management
New York
– -$248K -16,789 Closed
ACM
253
Advent Capital Management
New York
– -$207K -14,000 Closed
HSBC Holdings
254
HSBC Holdings
United Kingdom
– -$199K -13,308 Closed
CC
255
Corton Capital
Ontario, Canada
– -$159K -10,732 Closed
GFA
256
Gallagher Fiduciary Advisors
Illinois
– -$155K -10,463 Closed
AI
257
Atria Investments
North Carolina
– -$154K -10,417 Closed
Lazard Asset Management
258
Lazard Asset Management
New York
– -$80K -5,461 Closed
HT
259
Headlands Technologies
Illinois
– -$73.1K -4,936 Closed
Raymond James Financial
260
Raymond James Financial
Florida
– -$33.4K -2,260 Closed
Northwestern Mutual Wealth Management
261
Northwestern Mutual Wealth Management
Wisconsin
– -$3.02K -204 Closed
EC
262
Elequin Capital
New York
– -$740 -50 Closed
PWA
263
Physician Wealth Advisors
Utah
– -$504 -34 Closed
TPWA
264
Twin Peaks Wealth Advisors
California
– -$17 -1 Closed
7 8 9 10
11

TVTX Hedge Fund Activity: Q3 2025 in Review

238 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q3 2025, worth a combined $2.41B — up 62% from $1.49B a quarter earlier.

Buyers outnumbered sellers: 56 funds opened new TVTX positions and 27 closed out — a net gain of 29 holders — while 72 added to existing stakes and 80 trimmed.

The largest buyer was Perceptive Advisors, adding an estimated $55.7M. The largest seller was Armistice Capital, cutting an estimated $40.5M.

  • 238 institutional investors held Travere Therapeutics (TVTX) as of Q3 2025, up from 211 in Q2 2025.
  • Funds reported $2.41B of Travere Therapeutics stock for Q3 2025, up 62% quarter-over-quarter.
  • 56 funds opened new Travere Therapeutics positions in Q3 2025 and 27 closed out, a net change of +29 holders.
  • The largest Travere Therapeutics buyer in Q3 2025 was Perceptive Advisors, an estimated $55.7M added.
  • The largest Travere Therapeutics seller in Q3 2025 was Armistice Capital, an estimated $40.5M sold.

Based on aggregated 13F filings for Q3 2025.